<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02049385</url>
  </required_header>
  <id_info>
    <org_study_id>140041</org_study_id>
    <secondary_id>14-M-0041</secondary_id>
    <nct_id>NCT02049385</nct_id>
  </id_info>
  <brief_title>Does Enhanced Glutamate Transporter Function Produce Antidepressant Effects in People With Major Depression?</brief_title>
  <official_title>A Pathophysiological Study to Determine if Enhancing Glutamate Transporter Function Produces Antidepressant Effects in Patients With Major Depressive Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:&#xD;
&#xD;
      - At least one third of individuals with major depressive disorder (MDD) remain&#xD;
      treatment-refractory after receiving currently available antidepressants underscoring the&#xD;
      urgent need for new antidepressant therapies. Of the novel pharmacotherapeutic strategies&#xD;
      seeking to rapidly alleviate depressive symptoms, glutamatergic modulators have emerged as&#xD;
      promising potential targets. The present study sought to examine the potassium (KATP) channel&#xD;
      activator diazoxide as a possible treatment for MDD. Diazoxide increases glutamate uptake&#xD;
      from the synaptic cleft by activating the KATP channel to chronically increase expression of&#xD;
      the excitatory amino acid transporter (EAAT)-2 system in glial cells. Diazoxide is&#xD;
      FDA-approved for the treatment of sulfonylurea-induced hypoglycemia, hypoglycemia due to&#xD;
      hyperinsulinemia, and hypertension.&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
      - To assess the ability of diazoxide, potassium channel activator, to improve overall&#xD;
      depressive symptomatology in patients with treatment-resistant MDD currently experiencing a&#xD;
      major depressive episode. The efficacy of a three-week course of diazoxide will be compared&#xD;
      to three weeks of placebo. The MADRS will serve as the main outcome measure&#xD;
&#xD;
      Eligibility:&#xD;
&#xD;
      - Adults 18 to 65 years old with MDD who are currently depressed without psychotic features.&#xD;
&#xD;
      Design:&#xD;
&#xD;
        -  Study Phase I (Day -28 to 0):&#xD;
&#xD;
           -- Screen and taper off medications (Days -28 to -14): Prior to consenting to this&#xD;
           study, subjects will have undergone a screening consisting of laboratory tests,&#xD;
           psychiatric and medical history, and psychiatric and physical examinations under&#xD;
           protocol 01-M-0254, &quot;The Evaluation of Patients with Mood and Anxiety Disorders and&#xD;
           Healthy Volunteers&quot;. After consenting to this study, patients will be tapered off&#xD;
           medications. Medications allowed and not allowed are listed in Appendix 1. Patients will&#xD;
           be reminded to report all drugs, OTC products, and other agents to the investigators so&#xD;
           that they can screen to avoid interactions that might make participation unsafe or might&#xD;
           confound the research results. Patients are expected to meet all inclusion and exclusion&#xD;
           criteria before medications are tapered (which is usually 1-2 weeks long). Subjects who&#xD;
           are not taking medications will enter the drug-free period directly. All participants&#xD;
           must have a score of ≥20 on the MADRS at screening and baseline of Study Phase I.&#xD;
           Subjects who do not have a score of ≥20 on the MADRS by the end of Study Phase I will be&#xD;
           excluded and will receive standard treatment.&#xD;
&#xD;
        -  Drug-free period (Day -14 to day 0):&#xD;
&#xD;
           -- Subjects will begin a 2-week drug-free period prior to the administration of&#xD;
           diazoxide or placebo.&#xD;
&#xD;
        -  Study Phase II (Day 0 to 56):&#xD;
&#xD;
             -  In this study phase, subjects will be blindly randomized to receive either&#xD;
                diazoxide 200-400 mg/day (given BID) or a placebo administered daily by mouth for&#xD;
                three weeks. All patients except those who have a 50% or greater decrease in MADRS&#xD;
                from baseline at the end of the first cross over point will cross over. To avoid&#xD;
                carry-over effects between the different test sessions, there will be an interval&#xD;
                of 14-21 days, pending response to test session 1. Subjects will then be blindly&#xD;
                crossed over to the second experimental condition (either diazoxide or placebo) for&#xD;
                another three weeks. All subjects who discontinue the study or who complete study&#xD;
                phase II will then receive either clinical treatment or the opportunity to&#xD;
                participate in another research protocol. Patients maintaining response to&#xD;
                treatment condition 1 after two weeks will receive an additional one week washout&#xD;
                before being crossed over to condition 2.The total duration of the study is&#xD;
                approximately 11-13 weeks. The duration of Study Phase I including the 14-day&#xD;
                drug-free period is approximately 4 weeks. Study phase II is 8-9 weeks long. Thus,&#xD;
                the total duration of the study is approximately 11-13 weeks, except for those&#xD;
                patients who were unmedicated at time of entry into the study and therefore do not&#xD;
                need to undergo the initial tapering off medications. Subjects will be required to&#xD;
                be hospitalized during the entire study. Passes will be permitted if the subject is&#xD;
                clinically stable and the pass does not interfere with the study or unit&#xD;
                procedures.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective:&#xD;
&#xD;
      To date, available pharmacological treatments for major depressive disorder (MDD) have proven&#xD;
      to be only modestly effective during the acute phase. We have been systematically testing&#xD;
      different glutamatergic modulators in patients with mood disorders in order to develop&#xD;
      improved therapeutics. A recent report found that the (beta)-lactam antibiotic ceftriaxone&#xD;
      increased glutamate uptake by increasing GLT1(EAAT2) function and had antidepressant-like&#xD;
      effects in animal models. Using the learned helplessness model of depression we developed&#xD;
      outbred lines, defined a new anatomy of helplessness, and determined that synaptic loss due&#xD;
      to excess extracellular glutamate appears to be involved in the pathophysiology of&#xD;
      helplessness; these animals show a 40% decrease in EAAT2 astrocytic transporter expression.&#xD;
      Together, these data suggest that astrocytic glutamate reuptake systems may be central to the&#xD;
      pathophysiology and treatment of depression, and that agents that directly increase&#xD;
      astrocytic glutamate uptake may represent a novel class of antidepressants.&#xD;
&#xD;
      With this protocol, we propose to test a specific new mechanism that uses diazoxide to&#xD;
      chronically increase expression of the glutamate transporter EAAT2, resulting in removal of&#xD;
      glutamate from the synaptic cleft. Diazoxide enhances glutamate uptake in glia by activating&#xD;
      ATP-sensitive potassium (KATP) channels. We expect that this effect will reduce excessive&#xD;
      glutamate transmission and be associated with acute antidepressant effects. The model&#xD;
      presented here is a clinically testable one. If successful, it may lead to the development of&#xD;
      a group of novel pharmacological treatments for major depressive disorder.&#xD;
&#xD;
      Study Population:&#xD;
&#xD;
      24 individuals with treatment-resistant major depressive disorder.&#xD;
&#xD;
      Design:&#xD;
&#xD;
      Male and female patients diagnosed with MDD, ages 18 to 65 years, currently experiencing a&#xD;
      major depressive episode, will be recruited for this study. The study will comprise the&#xD;
      double-blind crossover administration of either diazoxide (200-400 mg/day given orally) or&#xD;
      placebo. The study will assess the efficacy of three weeks of a glutamate transporter&#xD;
      enhancer (diazoxide, 200-400 mg/day given orally) compared with placebo in improving overall&#xD;
      depressive symptomatology in patients with treatment-resistant MDD. Other aims of the study&#xD;
      include: 1) determining whether changes in brain neurochemicals (glutamate) correlate with&#xD;
      antidepressant response (as measured by decreases in Montgomery-Asberg Depression Rating&#xD;
      Scale (MADRS) total scores) in response to diazoxide in patients with treatment-resistant&#xD;
      MDD; and 2) examining other potential biomarkers of response.&#xD;
&#xD;
      Outcome Measures:&#xD;
&#xD;
      Primary: MADRS total score. Secondary outcome measures: proportion of subjects achieving&#xD;
      remission (MADRS score less than or equal to 10) and response (more &lt;50% reduction from&#xD;
      baseline in MADRS total score); change from baseline in Beck Depression Inventory (BDI),&#xD;
      Hamilton Anxiety Rating Scale (HAM-A), Hamilton Depression Rating Scale (HAM-D), Visual&#xD;
      Analog Scale (VAS), and the Columbia Suicide Severity Rating Scale (C-SSRS) total scores.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Severe side effects &amp; lack of target engagement&#xD;
  </why_stopped>
  <start_date>January 3, 2014</start_date>
  <completion_date type="Actual">July 21, 2016</completion_date>
  <primary_completion_date type="Actual">July 21, 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MADRS Change at Day 7</measure>
    <time_frame>7 days</time_frame>
    <description>Change in Montgomery Asberg Depression Rating Scale (MADRS) from baseline to 7 days post-treatment. The range of values is from 0 - 60, with a higher score indicating increased depressive symptoms. A score of 7-19 indicates mild depression; 20-34 indicates moderate depression; &gt;34 indicates severe depression.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>Diazoxide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received 200-400 mg daily of diazoxide orally for three weeks; the dose was, adjusted depending on side effects and response.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received a matched placebo for three weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diazoxide</intervention_name>
    <description>A nondiuretic vasodilator thiazide-related agent</description>
    <arm_group_label>Diazoxide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:&#xD;
&#xD;
               -  18 to 65 years of age.&#xD;
&#xD;
               -  Women of child bearing potential must have a negative serum pregnancy test and&#xD;
                  confirmed (by the investigator) use of two effective methods of contraception&#xD;
                  (see below).&#xD;
&#xD;
               -  Each subject must be capable of understanding all required tests and examinations&#xD;
                  and must sign an informed consent document.&#xD;
&#xD;
               -  Subjects must fulfill DSM-IV criteria for MDD, single episode or recurrent&#xD;
                  without psychotic features, based on clinical assessment and confirmed by a&#xD;
                  structured diagnostic interview (SCID-P). Subjects must be experiencing a current&#xD;
                  major depressive episode of at least four weeks duration.&#xD;
&#xD;
               -  Subjects must have an initial score of at least 20 on the MADRS at screening and&#xD;
                  at baseline of study Phase I.&#xD;
&#xD;
               -  Subjects must have a current or past history of lack of response to two adequate&#xD;
                  antidepressant trials (may be from the same chemical class) operationally defined&#xD;
                  using the modified-Antidepressant Treatment History Form (ATHF).&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
          -  Current psychotic features or a current or past diagnosis of schizophrenia or any&#xD;
             other psychotic disorder as defined in the DSM-IV.&#xD;
&#xD;
          -  Subjects with a history of DSM-IV drug or alcohol dependency or abuse (except for&#xD;
             caffeine or nicotine dependence) within the preceding three months.&#xD;
&#xD;
          -  Head injury that results in loss of consciousness exceeding five minutes (for the&#xD;
             imaging component of the study).&#xD;
&#xD;
          -  Subjects with a DSM IV Axis II diagnosis of borderline or antisocial personality&#xD;
             disorder.&#xD;
&#xD;
          -  Pregnant or nursing women or women of child bearing potential not using two medically&#xD;
             accepted means of contraception (including oral, injectable, or implant birth control,&#xD;
             condoms, a diaphragm with spermicide; intrauterine devices (IUD); tubal ligation;&#xD;
             abstinence; or partner with vasectomy).&#xD;
&#xD;
          -  Serious, unstable medical illnesses including hepatic, renal, gastroenterologic,&#xD;
             respiratory, cardiovascular (including ischemic heart disease), endocrinologic,&#xD;
             neurologic, immunologic, or hematologic disease.&#xD;
&#xD;
          -  Subjects with hyperthyroidism or clinical hypothyroidism.&#xD;
&#xD;
          -  Subjects with one or more seizures without a clear and resolved etiology.&#xD;
&#xD;
          -  Clinically significant abnormal laboratory tests (including blood glucose).&#xD;
&#xD;
          -  Diabetes&#xD;
&#xD;
          -  Fasting plasma glucose concentration &gt;120 mg/dl&#xD;
&#xD;
          -  Upright diastolic blood pressure &lt;60mmHg on three occasions 30 minutes apart (based on&#xD;
             scheduled research measurements).&#xD;
&#xD;
          -  Treatment with a reversible MAOI within four weeks of study Phase II.&#xD;
&#xD;
          -  Treatment with fluoxetine within five weeks of study Phase II.&#xD;
&#xD;
          -  Treatment with any other disallowed concomitant medication 14 days before&#xD;
             randomization.&#xD;
&#xD;
          -  Treatment with clozapine or ECT within one month of randomization.&#xD;
&#xD;
          -  Lifetime history of deep brain stimulation.&#xD;
&#xD;
          -  Subjects who, in the investigator's judgment, pose a current serious suicidal or&#xD;
             homicidal risk.&#xD;
&#xD;
          -  Positive HIV test&#xD;
&#xD;
          -  Contraindications to MRI (metal in body, claustrophobia, etc)&#xD;
&#xD;
        No structured psychotherapy will be permitted during the study.&#xD;
&#xD;
        Definition of treatment-resistance&#xD;
&#xD;
        All subjects are required to have previously failed to respond to two adequate&#xD;
        antidepressant trials (may be from the same chemical class). Adequacy of antidepressant&#xD;
        trials will be determined via the clinician administered modified ATHF.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carlos A Zarate, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Mental Health (NIMH)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Aitken RC. Measurement of feelings using visual analogue scales. Proc R Soc Med. 1969 Oct;62(10):989-93. Review.</citation>
    <PMID>4899510</PMID>
  </reference>
  <reference>
    <citation>Akhondzadeh S, Mojtahedzadeh V, Mirsepassi GR, Moin M, Amini-Nooshabadi H, Kamalipour A. Diazoxide in the treatment of schizophrenia: novel application of potassium channel openers in the treatment of schizophrenia. J Clin Pharm Ther. 2002 Dec;27(6):453-9.</citation>
    <PMID>12472985</PMID>
  </reference>
  <reference>
    <citation>Altamura CA, Mauri MC, Ferrara A, Moro AR, D'Andrea G, Zamberlan F. Plasma and platelet excitatory amino acids in psychiatric disorders. Am J Psychiatry. 1993 Nov;150(11):1731-3.</citation>
    <PMID>8214185</PMID>
  </reference>
  <verification_date>July 2017</verification_date>
  <study_first_submitted>January 28, 2014</study_first_submitted>
  <study_first_submitted_qc>January 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 30, 2014</study_first_posted>
  <results_first_submitted>July 20, 2017</results_first_submitted>
  <results_first_submitted_qc>September 12, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">October 13, 2017</results_first_posted>
  <last_update_submitted>September 12, 2017</last_update_submitted>
  <last_update_submitted_qc>September 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glutamate</keyword>
  <keyword>Pathophysiology</keyword>
  <keyword>Depression</keyword>
  <keyword>Treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diazoxide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Diazoxide, Then Placebo</title>
          <description>Subjects received 200-400 mg daily of diazoxide orally for three weeks; the dose was adjusted depending on side effects and response.</description>
        </group>
        <group group_id="P2">
          <title>Placebo, Then Diazoxide</title>
          <description>Subjects received a matched placebo for three weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Participants</title>
          <description>Subjects received 200-400 mg daily of diazoxide orally for three weeks; the dose was, adjusted depending on side effects and response.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>MADRS Change at Day 7</title>
        <description>Change in Montgomery Asberg Depression Rating Scale (MADRS) from baseline to 7 days post-treatment. The range of values is from 0 - 60, with a higher score indicating increased depressive symptoms. A score of 7-19 indicates mild depression; 20-34 indicates moderate depression; &gt;34 indicates severe depression.</description>
        <time_frame>7 days</time_frame>
        <population>The analysis included those subjects who started treatment and completed treatment with Diazoxide or Placebo through at least 7 days.</population>
        <group_list>
          <group group_id="O1">
            <title>Diazoxide</title>
            <description>Subjects received 200-400 mg daily of diazoxide orally for three weeks; the dose was adjusted depending on side effects and response.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects received a matched placebo for three weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>MADRS Change at Day 7</title>
          <description>Change in Montgomery Asberg Depression Rating Scale (MADRS) from baseline to 7 days post-treatment. The range of values is from 0 - 60, with a higher score indicating increased depressive symptoms. A score of 7-19 indicates mild depression; 20-34 indicates moderate depression; &gt;34 indicates severe depression.</description>
          <population>The analysis included those subjects who started treatment and completed treatment with Diazoxide or Placebo through at least 7 days.</population>
          <units>percentage of change in units of scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="100"/>
                    <measurement group_id="O2" value="10" lower_limit="0" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Diazoxide</title>
          <description>Subjects received 200-400 mg daily of diazoxide orally for three weeks; the dose was adjusted depending on side effects and response.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Subjects received a matched placebo for three weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Akathisia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Irregular sleep phase</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Poor quality sleep</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Sedation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Decreased activity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Irregular breathing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Throat irritation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Skin irritation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>As only 1 participant completed both treatment arms, no formal statistical analysis of the primary outcome (MADRS) possible. Study halted due to severe side effects &amp; lack of target (KATP channel) engagement measured by insulin sensitivity index.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Zarate, Carlos</name_or_title>
      <organization>National Institute of Mental Health</organization>
      <phone>+1 301 451 0861</phone>
      <email>zaratec@mail.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

